- Home
- PASG
PASG
Passage Bio Inc.
as 07-26-2024 4:00pm EST
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.
| Founded: | 2017 | Country: | United States |
| Employees: | 85 | City: | PHILADELPHIA |
| Market Cap: | 54.2M | IPO Year: | 2020 |
| Target Price: | $9.00 | AVG Volume (30 days): | 182.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.53 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.57 - $1.79 | Next Earning Date: | 08-05-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Passage Bio Inc. (PASG)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Borthwick Kathleen | PASG | SVP, INTERIM CFO | Feb 10 '24 | Sell | $0.97 | 1,470 | $1,425.90 | 28,466 | SEC Form 4 |
| Borthwick Kathleen | PASG | SVP, Interim CFO | Dec 31 '23 | Sell | $0.91 | 10,672 | $9,711.52 | 25,936 | SEC Form 4 |
| Cale Edgar B. | PASG | GC & Corporate Secretary | Dec 31 '23 | Sell | $0.91 | 15,813 | $14,389.83 | 45,995 | SEC Form 4 |
| Forman Mark S | PASG | Chief Medical Officer | Dec 31 '23 | Sell | $0.91 | 15,813 | $14,389.83 | 45,269 | SEC Form 4 |
| Forman Mark S | PASG | CHIEF MEDICAL OFFICER | Aug 16 '21 | Sell | $0.97 | 1,638 | $1,588.86 | 48,631 | SEC Form 4 |
Latest Passage Bio Inc. News
PASG Breaking Stock News: Dive into PASG Ticker-Specific Updates for Smart Investing
Clinical Trials Arena
2 days ago
Passage Bio targets FDA to greenlight ALS gene therapy trial
Simply Wall St.
5 days ago
Is Passage Bio (NASDAQ:PASG) In A Good Position To Invest In Growth?
MT Newswires
10 days ago
Passage Bio Receives Positive Opinion From FDA on Plan to Expand Frontotemporal Dementia Drug Trial
GlobeNewswire
11 days ago
Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients
GlobeNewswire
2 months ago
Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewswire
2 months ago
Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award
Zacks
2 months ago
All You Need to Know About Passage Bio (PASG) Rating Upgrade to Buy
GlobeNewswire
2 months ago
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
Compare PASG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PASG Passage Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.